Journal
JOURNAL OF HEPATOLOGY
Volume 79, Issue 2, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2023.04.010
Keywords
End stage liver diseases; Liver transplantation; Ischemia reperfusion injury; Ischemia-free organ transplantation; Normothermic machine perfusion; Early allograft dysfunction
Categories
Ask authors/readers for more resources
Ischemia-reperfusion injury (IRI) is a significant concern in organ transplantation, but ischemia-free organ transplantation may provide a solution by avoiding IRI and improving outcomes.
Background & Aims: Ischemia-reperfusion injury (IRI) has thus far been considered as an inevitable component of organ transplantation, compromising outcomes, and limiting organ availability. Ischemia-free organ transplantation is a novel approach designed to avoid IRI, with the potential to improve outcomes.Methods: In this randomized-controlled clinical trial, recipients of livers from donors after brain death were randomly assigned to receive either an ischemia-free or a 'conventional' transplant. The primary endpoint was the incidence of early allograft dysfunction. Secondary endpoints included complications related to graft IRI. Results: Out of 68 randomized patients, 65 underwent transplants and were included in the analysis. 32 patients received ischemia-free liver transplantation (IFLT), and 33 received conventional liver transplantation (CLT). Early allograft dysfunction occurred in two recipients (6%) randomized to IFLT and in eight (24%) randomized to CLT (difference -18%; 95% CI -35% to - 1%; p = 0.044). Post-reperfusion syndrome occurred in three recipients (9%) randomized to IFLT and in 21 (64%) randomized to CLT (difference -54%; 95% CI -74% to -35%; p <0.001). Non-anastomotic biliary strictures diagnosed with protocol magnetic resonance cholangiopancreatography at 12 months were observed in two recipients (8%) randomized to IFLT and in nine (36%) randomized to CLT (difference, -28%; 95% CI -50% to -7%; p = 0.014). The comprehensive complication index at 1 year after transplantation was 30.48 (95% CI 23.25-37.71) in the IFLT group vs. 42.14 (95% CI 35.01-49.26) in the CLT group (difference - 11.66; 95% CI -21.81 to -1.51; p = 0.025).Conclusions: Among patients with end-stage liver disease, IFLT significantly reduced complications related to IRI compared to a conventional approach.Clinical trial registration: chictr.org. ChiCTR1900021158.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available